Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 545-557

  Liebes, Leonard ^a,b   Potmesil, Milan ^a   Kim, Tony ^a   Pease, Denise ^a   Buckley, Michael ^a   Fry, David ^a   Cho, John ^a   Adler, Howard ^a   Dar, Khalid ^a   Zeleniuch Jacquotte, Anne ^a   Hochster, Howard ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

ADENOMA, ISLET CELL; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; BIOPSY; BREAST NEOPLASMS; CELL LINE; DNA TOPOISOMERASES, TYPE I; ENDOMETRIAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HELA CELLS; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; SCLERODERMA, SYSTEMIC; STOMACH NEOPLASMS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 15444349406     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Champoux, J., and Dulbecco, R. An activity from mammalian cells that untwists superhelical DNA: a possible swivel for DNA replication. Proc. Natl. Acad. Sci. USA, 69: 143-146, 1972.
2. Liu, L., and Miller, K. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78: 3487-3491, 1981.
3. Juan, C. C., Hwang, J. L., Liu, A. A., Whang-Peng, J., Knutsen, T., Huebner, K., Croce, C. M., Zhang, H., Wang, J. C., and Liu, L. F. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosomal region 20ql2-13.2. Proc. Natl. Acad. Sci. USA, 85: 8910-8913, 1988.
4. Liu, L., and Wang, J. Supercoiling of the DNA template during transcription. Proc. Natl. Acad. Sci. USA, 84: 950-954, 1987.
5. Liu, L. Biochemistry of camptothecin. In: M. Potmesil and H. Pinedo (eds.). Camptothecins: New Anticancer Agents, pp. 9-19. Boca Raton, FL: CRC Press, 1995.
6. Lynn, R., Bjornsti, M. A., Caron, P. R., and Wang, J. C. Peptide sequencing and site-directed mutagenesis identify tyrosine-723 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase-1. Proc. Natl. Acad. Sci. USA, 86: 3559-3563, 1989.
7. Champoux, J. DNA is linked to the rat liver nicking-closing enzyme by a phosphodiester bond to tyrosine. J. Biol. Chem., 256: 4805-4809, 1981.
8. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
9. Porter, S., and Champoux, J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res., 17: 8521-8532, 1989.
10. Kohn, K. W, Ewig, R. A. G., Erickson, L. C., and Zwelling L. A. Measurement of strand breaks and crosslinks by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.). DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker Inc., 1981.
11. Bertrand, R., and Pommier, Y. Assessment of DNA damage in mammalian cells by DNA filter elution methodology. In: G. P. Studzinski, (ed.). Cell Growth and Apotosis, pp. 97-117. Newark, NJ: Oxford University Press, 1995.
12. Subramanian, D., Kraut, E., Staubus, A., Young, D. C., and Muller, M. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res., 55: 2097-2103, 1995.
13. Goldwasser, F., Bae, I., Valenti, M., Torres, K., and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res., 55: 2116-2121, 1995.
14. Perego, P., Capranico, G., Supino, R., and Zunino, F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anti-Cancer Drugs, 5: 645-649, 1994.
15. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
16. Tsao, Y. P., Russo, A., Nyamuswa, G., Silber, R., and Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res., 53: 5908-5914, 1993.
17. Hsiang, Y., Lihou, M., and Liu, L. Arrest of replication forks by drug-stabilized topoisomerase-1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
18. cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
19. Nelson, E. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
20. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
21. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
22. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
23. Burton, K. Determination of DNA concentration with diphenylamine. Methods Enzymol., 12: 163-167, 1967.
24. Pollard, K. M., Reimer, G., and Tan, E. M. Autoantibodies in scleroderma. Clin. Exp. Rheumatol., 7 (Suppl. 3): 57-62, 1989.
25. Sturgess, A. Recently characterized autoantibodies and their clinical significance. Aust. N. Z. Med., 22: 279-289, 1992.
26. Maul, G. G, French, B. T., Van Vennrooij, W. J., and Jimenez, S. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc. Natl. Acad. Sci. USA, 83: 5145-5149, 1986.
27. Shero, J. H., Bordwell, B., Rothfield, N. F., and Earnshaw, W. C. High titers of autoantibodies to topoisomerase-1 (SCL-70) in sera from scleroderma patients. Science (Washington DC), 231: 737-740, 1986.
28. Wang, J. DNA topoisomerases. Annu. Rev. Biol., 54: 665-697, 1985.
29. Potmesil, M., Hsiang, Y., Liu, L., Bank, B., Grossberg, H., Kirschenbaum, S., Forlenza, T., Penziner, A., Kanganis, D., Knowles, D., Traganos, F., and Silber R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA/cleavage and low levels of DNA topoisomerase II. Cancer Res., 48: 3537-3543, 1988.
30. Beijnen, J., Smith, B. R., Keijer, W. J., Van Gijn, R., Ten Bokkel Huinink, W. W., Viasveld, L. T., Rodenhuis, S., and Underberg W. J. M. High-performance Chromatographic analysis of the new antitumor drug SK&F 104864-A (NSC609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
31. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. Phase I trial of low-dose continuous topotecan infusion (7-21 days) an active and well-tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
32. Gabrielsson, J., and Weiner, D. Pharmacokinetic and Pharmacody-namic Data analysis. Concepts and Applications, pp. 423-434. Stockholm: Swedish Pharmaceutical Press, 1994.
33. Rowland, M., and Tozer, T. In: M. Rowland and T. Tozer (eds.). Clinical Pharmacokinetics. Concepts and Applications, Ed. 3, p. 173. Philadelphia: Williams & Wilkins, 1995.
34. Liu, L. F., Duann, P., Ching-Tai, L., D'Arpa, P., and Jiaxi, W. Mechanism of action of camptothecin. In: P. Pantazis, B. C. Giovanella, and M. L. Rothenberg (eds.). The Camptothecins: From Discovery to the Patient, pp. 44-49. New York: The New York Academy of Sciences, 1996.
35. Rowinsky E. K., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
36. Covey, J. M., Axel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016-5022, 1989.
37. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Blum, R., and Zeleniuch-Jacquotte, A. Effect of prolonged topotecan infusion on topoiosomerase I levels: a Phase I and pharmacodynamic study. Clin. Cancer Res., 3: 1245-1252, 1997.